Drug Type Peptides |
Synonyms- |
Target |
Action antagonists |
Mechanism αvβ3 antagonists(Integrin alpha-V/beta-3 antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Chronic Kidney Diseases | Preclinical | - | 07 Nov 2025 | |
| Chronic Kidney Diseases | Preclinical | - | 07 Nov 2025 | |
| Diabetic Nephropathies | Preclinical | - | 07 Nov 2025 | |
| Diabetic Nephropathies | Preclinical | - | 07 Nov 2025 | |
| Glomerulosclerosis, Focal Segmental | Preclinical | - | 07 Nov 2025 | |
| Glomerulosclerosis, Focal Segmental | Preclinical | - | 07 Nov 2025 | |
| Proteinuria | Preclinical | - | 07 Nov 2025 | |
| Proteinuria | Preclinical | - | 07 Nov 2025 |





